Collaboration aims to help pharmaceuticals drive efficiencies and business value.
In association with Amazon Web Services (AWS), Eversana revealed plans to fast-track the use of artificial intelligence (AI) in the life sciences sector. Through this association, the organizations plan on implementing the technology to help pharmaceutical and life science manufacturers drive efficiencies and business value while improving patient outcomes.
Combining Eversana’s capabilities in AI with AWS’s Amazon Bedrock AI applications, the teams will work to identify, develop, and deploy high-impact solutions across the pharmaceutical commercialization value chain. According to a company press release, planned applications include:
"We believe we are at an inflection point in the life sciences industry with the rising influence of AI to transform capabilities and reimagine everything from customer experiences and omnichannel engagement to software development and operating models," said Jim Lang, CEO, Eversana, in the company release. "Companies that find the optimal balance of human and AI-powered services will leap ahead in every industry, and pharma is no different. Together with AWS, our goal is to bring AI across the life sciences industry or 'pharmatize it,' shaping the future of digital transformation, driving value for our clients and making a remarkable difference in the lives of patients."
Reference: EVERSANA & Amazon Web Services to "Pharmatize" Artificial Intelligence across the Life Sciences Industry. PR Newswire. July 24, 2023. Accessed July 24, 2023. https://www.prnewswire.com/news-releases/eversana--amazon-web-services-to-pharmatize-artificial-intelligence-across-the-life-sciences-industry-301883377.html
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.